SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 206.36+1.4%Nov 26 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Wallace Rivers who wrote (27918)2/6/1999 11:44:00 AM
From: Henry Niman  Read Replies (3) of 32384
 
It's my impression that LGND has put together a strong sales force. Most of LGND's senior management came from the large pharmas, so they should have a good understanding of what it takes to sell drugs. With the number of FDA approved drugs growing to 4-6 in the next 12-15 months, LGND's new US sales force (as well as the one being formed in Europe), will have a number of new and exciting developments to pass onto physicians.

Traditional valuations are usually based on profits, and LGND's profits are not expected until the last quarter of this year. After that, earnings growth is expect to be quite strong, which should help LGND achieve its pricing potential.

As Bear Stearns indicated on Wednesday, Biotechs traditionally make their biggest price moves right after drugs are approved, and David Molowa did not expect LGND to be an exception.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext